Drug Type T-lymphocyte cell therapy |
Synonyms NEO STC 01, NEO-STC-01 |
Target |
Mechanism RAS inhibitors(RAS type GTPase family inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Preclinical | US | 20 Nov 2019 | |
Pancreatic Carcinoma | Preclinical | US | - |